Theravance Biopharma R&d Ip, LLC

Bristol-myers Squibb Compnay

Marta Dabros

Venkat R Thalladi

Jerry Nzerem

Robert Murray McKinnell

Paul Ross Fatheree

Miroslav Rapta

Gary E L Brandt

Lan Jiang

Ryan Hudson

Erik Fenster

Jennifer Kozak

Tom M Lam

Noah M Benjamin

John R Jacobsen

Melissa Fleury

T G Murali Dhar

Alaric J Dyckman

Hai-Yun Xiao

Cameron Smith

Anne-Marie Beausoleil

Pierre-Jean Colson

Lori Jean Van Orden

Chenkou Wei

Steven D E Sullivan

Glenn D Crater

Mandy Loo

Melanie A Kleinschek

Hao Zhang

Gene Timothy Fass

Breena Gloriana Fraga

Anthony Francesco Palermo

Daniel Richard Roberts

Diana Jin Wang

Eric J Chan

T G Dhar

Steven De Sullivan

Gary El Brandt

Gary EL Brandt

The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.

Pyrimidine compound as JAK kinase inhibitor

The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

JAK kinase inhibitor compounds for treatment of respiratory disease

The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.

Fused imidazo-piperidine JAK inhibitor compound

The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

The present invention provides crystalline hydrates of the oxalate and succinate salts of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol. The invention also provides pharmaceutical compositions comprising such crystalline hydrates, methods of using such crystalline hydrates to treat respiratory and other diseases, and processes useful for preparing such crystalline oxalate and succinate hydrates.

Crystalline forms of a JAK inhibitor compound

The instant invention provides crystalline forms of (S,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.

Crystalline forms of a factor XIa inhibitor

Disclosed are compounds of Formula (I) and/or a salt thereof; wherein R is &#x2014;OH or &#x2014;OP(O)(OH). Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Tetrahydronaphthalenyl compounds useful as sipi agonists

Growing community of inventors

Foster City, CA, United States of America

Marta Dabros